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Abstract: Eleven primer pairs were developed for the identification of Neisseria gonorrhoeae.
The sensitivity and specificity of these primers were evaluated by Real Time (RT)-PCR melt curve
analyses with DNA from 145 N. gonorrhoeae isolates and 40 other Neisseria or non-Neisseria species.
Three primer pairs were further evaluated in a hydrogel-based RT-PCR detection platform, using DNA
extracted from 50 N. gonorrhoeae cultures. We observed 100% sensitivity and specificity in the
hydrogel assay, confirming its potential as a point-of-care test (POCT) for N. gonorrhoeae diagnosis.
Keywords: Neisseria gonorrhoeae; molecular diagnosis; RT-PCR; hydrogel
1. Introduction
Neisseria gonorrhoeae, the second most prevalent bacterial sexually transmitted infection
(STI) globally, causes 78 million new gonorrhea infections annually [1]. Rates of antimicrobial resistant
(AMR) gonorrhea are rising worldwide [2]. Left untreated, gonococcal infections can cause severe and
potentially life-threatening disease and reproductive complications, especially in women, including
infertility or involuntary death of the fetus [2,3]. With no immunization available, the only way to
eliminate infection is with effective antibiotic therapy [4,5].
Early diagnosis of infection, preferably at the patient’s first contact with the health care system,
is vital for proper control of N. gonorrhoeae [6]. Traditional diagnosis of gonorrhea largely relied on
microscopy and or culture of the organism from urogenital specimens. Highly sensitive and specific
nucleic acid amplification tests (NAATs) have replaced these tests in resource rich settings [7–10].
In many resource poor settings, either the appropriate laboratory facilities are not available at the
primary health care level, or the costs associated with diagnosis are unaffordable. In these instances,
patients are treated empirically based on symptoms (i.e., syndromic management) [11,12]. Syndromic
management often fails to identify asymptomatic infections and nay leave a large population of
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people at risk for ongoing transmission and severe complications [13,14]. Therefore, it is of the utmost
importance to design rapid, easy to perform tests that can provide early diagnosis of N. gonorrhoeae
even in asymptomatic patients.
An important factor contributing to the rising prevalence of gonorrhea is treatment delay, whereby
a patient may wait for a positive diagnostic test result before treatment is initiated [15]. Sometimes,
despite the availability of laboratory facilities, the delays in reporting results severely hinders timely
treatment [6]. It has been shown by mathematical modeling that a rapid test with a sensitivity as low as
63% can drastically increase the number of patients treated, rather than waiting for a highly sensitive,
yet slower test [16]. Likewise, although culture is considered the gold standard for a positive diagnosis,
the number of infected individuals diagnosed by a rapid test and in turn successfully treated can
outnumber the number of patients who return for treatment following extensive diagnostic procedures
such as culturing and more sensitive NAATs [17]. Furthermore, viable organisms are required for
culturing. Improper handling and transportation can reduce the viability of N. gonorrhoeae leading to
false negative results. However, with NAATs, the viability of the organism is not a concern [18,19].
The development of point-of-care tests (POCTs) for an STI such as gonorrhea is recognized as a
vital approach to improve timely diagnosis [13,14,20–22]. Although POCTs are commercially available
for the diagnosis of N. gonorrhoeae, many of these tests do not fit the ASSURED criteria important
for STI diagnosis tests, such as affordability, sensitivity, specificity, user friendliness, robustness,
and rapidness [13,21]. A reliable and rapid diagnostic test for N. gonorrhoeae would be a critical
advancement in diagnostic capability.
The portable hydrogel-based RT-PCR method, developed by Aquila Diagnostic Systems Inc.
Edmonton AB, Canada, is a rapid diagnostic platform utilizing Real Time Polymerase Chain Reaction
(RT-PCR) melt curve analysis to amplify nucleic acids directly in clinical specimens and report the
presence of specific genetic targets [23]. This system has successfully detected blood-borne infectious
diseases such as malaria, BK virus, and herpes simplex virus [23–25]. We developed and evaluated
eleven diagnostic primer pairs for the identification of N. gonorrhoeae. We then evaluated three of these
primers with the hydrogel-based detection method to assess the potential of this method for further
development as a POCT.
2. Results
2.1. Evaluation of N. gonorrhoeae Diagnostic Primer Pairs
From the eleven primer pairs tested (Table 1), nine primer pairs (3, 8-3, 8-4, 13, 16, 17-1, 17-2,
21-5, 31-2) amplified every N. gonorrhoeae isolate tested (n = 130) (Table 2). Primer pair 2 did not
amplify one of the 130 N. gonorrhoeae isolates. Primer pair 31-3 did not amplify 28 of the 130 N.
gonorrhoeae isolates. Primer pairs 2, 3, 8-4, 16, 17-1, 17-2, 21-5, 31-2, and 31-3 did not amplify any
of the non-N. gonorrhoeae or non-Neisseria species. However, primer pair 8-3 amplified DNA from
Neisseria flava, Neisseria lactamica, and Neisseria polysacchareae. Primer pair 13 amplified DNA from
N. flava, Neisseria subflava, Neisseria mucosa, N. lactamica, Neisseria perflava, Neisseria flavescens, and
N. polysacchareae (Table 2). The limit of detection of the primers was assessed by serially diluting
(10 ng/µL to 0.000001 ng/µL) genomic DNA from N. gonorrhoeae strain WHO-M. After 30 cycles of
PCR, all the primers were able to detect gonococcal concentrations as low as 0.001 ng/uL.
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Table 1. Primer sequences used in this study for detection of N. gonorrhoeae, their respective targets
and copy numbers present in the N. gonorrhoeae genome.
Primer ID
(product length) Sequence (5’->3’)

















Primer 8-3 (132bp) NGO0773, NGO1200, NGO1703,
NGO1137, NGO1164, NGO1262,
NGO1641
7 BD ProbeTec GCQx
Forward CAGAAGCCTACGGACGAGCA
Reverse CGCATATGCTTTGGCCGCTT






Primer13 (138bp) NGO0773, NGO1137, NGO1703,
NGO1164, NGO1200, NGO1262,
NGO1641

































a The primer sequences presented in this manuscript are the subject of a United States utility patent (#62/088,332).
b Locus Tag ID in the NCBI database. c Number of targets on N. gonorrhoeae FA1090 genome.







2 a 3 8-3 b 8-4 13 b 16 17-1 17-2 21-5 31-2 31-3
N. gonorrhoeae 130 129 130 130 130 130 130 130 130 130 130 102
N. flava 2 0 0 1 0 2 0 0 0 0 0 0
N. subfla va 2 0 0 0 0 1 0 0 0 0 0 0
N. elongata 2 0 0 0 0 0 0 0 0 0 0 0
N. mucosa 3 0 0 0 0 1 0 0 0 0 0 0
N. lactamica 4 0 0 2 0 2 0 0 0 0 0 0
N. perflava/sicca 5 0 0 0 0 3 0 0 0 0 0 0
N. flavescents c 2 0 0 0 0 1 0 0 0 0 0 0
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Table 2. Cont.
N. polysacchareae 4 0 0 1 0 2 0 0 0 0 0 0
Other Neisseria
species d 6 0 0 0 0 0 0 0 0 0 0 0
Non-Neisseria
species e 10 0 0 0 0 0 0 0 0 0 0 0
a Primers amplified regions with partial homology to DR9 repeats used in cobas 4800 CT/NG Test (Roche Molecular
Diagnostics, Pleasanton CA, USA). b Primers amplified regions with partial homology to targets used in BD ProbeTec
GC Qx Amplified DNA Assay (Becton Dickinson and Company, Franklin Lakes NJ, USA). c Neisseria flavescens.
d Neisseria animaloris (1), Neisseria cinerea (2), Neisseria menengitidis (1), Neisseria wadsworthii (1), Neisseriaweaverii (1).
e Enterococcus faecalis (1), Enterococcus faecium (1), Escherichia coli (1), lebsiella oxytoca (1), Lactobacillus jensenii (1),
Moraxella catarrhalis (1), Pseudomonas aeruginosa (1), Salmonella enterica serovar Typhimurium (1), Staphylococcus
aureus (1), and Staphylococcus epidermis (1).
2.2. Optimization of the Hydrogel System and Comparison with RT-PCR Methods
The ability of primers 3, 17-1, and 21-5 to identify genomic DNA from N. gonorrhoeae strains
WHO F, WHO P, WHO G, WHO K, and WHO N in the hydrogel system was analyzed using RT-PCR
(Table 3). To optimize the performance of the hydrogel system for N. gonorrhoeae, different parameters
for hydrogel and RT-PCR were assessed. In testing for the most effective concentration of SYBR-Green,
we determined that with 1× SYBR-Green (pre-mixed in the desiccated gel), primer pair 3 produced
melt curve temperatures (Tm values) similar to previously established Tm values (80.5 ◦C) with control
methods. However, with primer pairs 17-1 and 21-5, 2× SYBR-Green was required for established Tm
values (85.0 ◦C). Therefore, 2× SYBR-Green was chosen for subsequent experiments. Further, with our
primer pairs, we determined that optimal amplification occurred with 30 PCR cycles, which differs
from the hydrogel manufacturer’s recommendation of 40 cycles.
Table 3. The effect of SYBR-Green concentration on melt curve temperature (Tm values) of five N.
gonorrhoeae strains, with primer pairs 3, 17-1, and 21-5.
Strain
Melt Curve Temperature (◦C)













WHO-F 80.49 81.52 83.90 84.64 84.05 84.84
WHO-G 80.78 81.82 84.05 84.64 83.90 84.79
WHO-K 80.49 81.97 84.05 84.49 84.20 84.79
WHO-N 80.63 81.82 83.90 84.49 84.05 84.79
WHO-P 80.93 81.97 83.90 84.64 84.05 84.79
a Expected Tm values for primer pair 3—80.5 ◦C; primer pair 17-1—85.0 ◦C; primer pair 21-5—85.0 ◦C.
The performance of the hydrogel method with increasing concentrations of DNA (50, 70, or
100 ng/µL) was assessed using genomic DNA from 50 N. gonorrhoeae positive cultures (Table 4: Panel 2),
WHO N. gonorrhoeae reference strains (n = 5; positive control) and non-N. gonorrhoeae strains (n = 4;
negative control). Based on the melt curve (Tm) temperatures (primer pair 3, 80.5 ◦C; primer pairs
17-1 and 21-5, 85.0 ◦C), primer pair 3 with 50 ng/µL DNA identified 44 N. gonorrhoeae isolates.
With 70 ng/µL DNA, primer pair 3 identified 46 isolates and with 100 ng/µL DNA identified all 50 N.
gonorrhoeae isolates (Table 5). Thus, primer pair 3 had 88%, 92% and 100% sensitivity with 50, 70 and
100 ng/µL DNA respectively. The specificity of primer pair 3 was 100% with all DNA concentrations
tested. Primer pair 17-1, irrespective of the DNA concentration tested, identified all 50 N. gonorrhoeae
isolates and had 100% sensitivity and specificity. Primer pair 21-5 identified 47 N. gonorrhoeae isolates
with 50 ng/µL DNA and had a sensitivity of 94% and a specificity of 100%. With 70 ng/µL and
100 ng/µL DNA, primer pair 21-5 identify all 50 isolates and had 100% sensitivity and specificity.
Primer pairs 3 and 17-1 in the control RT-PCR method identified all 50 N. gonorrhoeae isolates and had a
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sensitivity of 100%. Primer pair 21-5 identified 48 isolates with a sensitivity of 96%. One non-Neisseria
species (Escherichia coli) was incorrectly identified as N. gonorrhoeae positive by primer pair 3 in the
RT-PCR control method, thereby giving a specificity of 67% (Table 5). With primer pairs 17-1 and
21-5, all the negative control isolates (E. coli, Lactobacillus jensenii, Neisseria elongata, Neisseria subflava,
and Salmonella enterica serovar Typhimurium) were correctly ascertained as N. gonorrhoeae negative,
giving a specificity of 100%.
Table 4. N. gonorrhoeae, non-N. gonorrhoeae, and non-Neisseria isolates used in this study.








the Caribbean 28 Dillon Culture Collection
Non-N. gonorrhoeae b Canada 30 NML a






the Caribbean 9 Dillon Culture Collection
WHO 5 [29]
Non-N. gonorrhoeae c Canada 2 NML
Non-Neisseria species c Canada 3 NML
a National Microbiology Laboratory. b One isolate of: Enterococcus faecalis, Enterococcus faecium, Escherichia coli,
Klebsiella oxytoca, Lactobacillus jensenii, Moxarella catarrhalis, Neisseria animaloris, Neisseria cinerea, Neisseria elongata,
Neisseria flava, Neisseria lactamica, Neisseria menengitidis, Neisseria mucosa, Neisseria perflava, Neisseria polysacchareae,
Neisseria sicca, Neisseria subflava, Neisseria wadsworthii, Neisseria weaverii, Pseudomonas aeruginosa, Salmonella enterica
serovar Typhimurium, Staphylococcus aureus, and Staphylococcus epidermis. c One isolate of: E. coli, L. jensenii, N. elongata,
N. subflava, and S. enterica serovar Typhimurium.
Table 5. Evaluation of hydrogel and RT-PCR methods using varying concentrations of N. gonorrhoeae
DNA (n = 50) a and diagnostic primer pairs 3, 17-1, and 21-5.
Primer Pair Method DNA Conc.(ng/µL)
No N. gonorrhoeae
Isolates Identified as
per Tm value (n = 50) b
Positive Ct





3 Hydrogel 50 44 0 88 100
3 Hydrogel 70 46 33 92 100
3 Hydrogel 100 50 0 100 100
3 Hydrogel+4× SYBR d 100 50 50 100 100
3 RT-PCR control 70 50 50 100 67 c
17-1 Hydrogel 50 50 0 100 100
17-1 Hydrogel 70 50 0 100 100
17-1 Hydrogel 100 50 0 100 100
17-1 RT-PCR control 70 50 50 100 100
21-5 Hydrogel 50 47 0 94 100
21-5 Hydrogel 70 50 0 100 100
21-5 Hydrogel 100 50 0 100 100
21-5 RT-PCR control 70 48 49 96 100
a Controls—WHO N. gonorrhoeae reference strains (n = 5; positive control) and non-N. gonorrhoeae and non-Neisseria
strains (n = 4; negative control). b Number of N. gonorrhoeae isolates identified as per the melt curve temperature
(Tm) and threshold cycle (Ct) values. Isolates with negative Ct values had a positive melt curve temperature (Tm).
c One Non-N. gonorrhoeae isolate identified as N. gonorrhoeae positive. d Hydrogel method pre-contained 2×
SYBR-Green dye. For this assay, extra, fresh 2× SYBR-Green dye was added for a final concentration of 4×
SYBR-Green dye.
With the hydrogel method and primer pair 3, 33 samples had positive threshold cycle (Ct) values
when using 70 ng/µL DNA. However, with 50 ng/µL and 100 ng/µL DNA, none of the samples
had positive Ct values. Similarly, with primer pairs 17-1 and 21-5, all 50 samples had negative Ct
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values. In contrast, when using the control RT-PCR method and primer pair 3, all 50 samples had
positive Ct values. Likewise, with primer pair 17-1, all 50 samples had positive Ct values. With primer
pair 21-5, 49 samples had positive Ct values. To consider if the hydrogel system was interfering with
the fluorescence reading, extra, fresh SYBR-Green (commercially made 2× SYBR-Green) was added
to the reaction mixture of samples with the hydrogel method. These reaction mixtures pre-contained
2× SYBR-Green incorporated in to the desiccated gel. The addition of total 4x and fresh SYBR-Green
significantly improved the results from the hydrogel method and produced Ct values similar to that
obtained with RT-PCR control method (Table 5).
3. Discussion
We developed and evaluated novel primers in a hydrogel platform as a potentially useful POCT for
N. gonorrhoeae diagnosis. This system is rapid and requires minimal sample preparation. The hydrogel
system introduces a state-of-the-art portable diagnostic approach to bringing a detection platform to
clinicians and to remote locations, as this system contains desiccated primers, polymerases and other
PCR components, thereby enabling the prompt delivery of results. Only the patient sample would
need to be added to the system prior to PCR amplification. As such, this system does not require a
cold chain (i.e., refrigeration) to preserve the PCR reagents, a major obstacle to delivering diagnostic
tests to remote locations.
A recent review evaluated POCTs for N. gonorrhoeae [13]. The tests evaluated include lateral
flow immunochromatographic test (ICT) formats, i.e., the Binax NOW Gonorrhoea Test (Inverness),
the GC Check (PATH, Seattle, WA, USA) and, the ACON format tests (ACON Laboratories, San Diego,
CA, USA); an optical immunoassay test (OIA), the BioStar (ThermoFisher/BioStar, Boulder, CO, USA);
and a nucleic acid amplification test, the GeneXpert CT/NG Assay (Cepheid, Sunnyvale, CA, USA).
The performance of the ICTs was variable with sensitivities ranging from 94%, 70%, and 12.5% and
specificities from 96%, 97%, and 99.8% for Binax NOW, GC Check and ACON format tests, respectively.
The OIA BioStar test had a sensitivity of 60% and a specificity of 89%. The ICTs and the OIA had 5 or
more steps and took 25 to 40 minutes to obtain results [13,14]. These tests generally fail to meet the
high levels of sensitivity and specificity required for a POCT. The GeneXpert CT/NG Assay is the only
commercial NAAT-based POCT for N. gonorrhoeae diagnosis and has high sensitivity (95.6–98%) and
specificity (99.9–100%) which is dependent on the specimen type [13,30–33]. This assay requires 3 steps
and takes 90 minutes to produce results [31]. The limiting factor about considering the GeneXpert as a
POCT is affordability and portability of the equipment.
The currently available United States Food and Drug Administration approved commercial
NAAT systems for N. gonorrhoeae identification primarily rely on a single target detection strategy [34].
These tests include the Abbott Real Time CT/NG assay which targets a 48bp sequence within
the N. gonorrhoeae opa gene (Abbott Laboratories, Abbott Park, IL, USA), the Aptima COMBO
2 assay and the Aptima GC assay which target specific regions within N. gonorrhoeae 16S rRNA
(Hologic/Gene-Probe Inc., San Diego, CA, USA), the BD ProbeTec ET CT/GC Amplified DNA assay
and BD ProbeTec Qx GC Amplified DNA Assay which target the chromosomal pilin gene-inverting
protein homologue (Becton Dickinson and Company, Sparks, MD, USA), the Cobas 4800 CT/NG
which targets the DR-9 region (Roche Diagnostics, Indianapolis, IN, USA) and the GeneXpert CT/NG
Assay (Cepheid, Sunnyvale, CA, USA) which uses two non-contiguous chromosomal targets (NG2
and NG4) of N. gonorrhoeae [7,30,31,34,35].
The hydrogel method we evaluated had 100% sensitivity and specificity using DNA from N.
gonorrhoeae cultures. The system remains to be tested using clinical specimens of N. gonorrhoeae such as
urines or self-collected vaginal or rectal swabs. One complication that arose with the hydrogel method
was that, despite having a positive N. gonorrhoeae diagnosis by melt curve (Tm) analysis, most samples
contained negative threshold cycle (Ct) values. Therefore, we considered that the hydrogel system
was interfering with the fluorescence reading, thereby giving Ct values lower than the threshold value
(i.e., negative Ct values). Addition of extra, fresh 2× SYBR-Green to the hydrogel reaction mixture
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pre-containing 2× SYBR-Green, for a final concentration of 4× SYBR-Green resulted in favorable
Ct values. The hydrogel has been successfully used for the detection of other pathogens such as
Herpes simplex virus from raw genital swabs, Plasmodium falciparum, BK virus, human platelet antigen
1 (HPA1), and fibroblast growth factor receptor 2 (FGFR2) from unprocessed blood samples [23–25].
Furthermore, the <2-hour time frame from specimen collection to results makes this test a potentially
much simpler and user-friendly second molecular POCT.
The genomic targets of three of our primer pairs have partial homology with genomic targets
used in two commercial assays. Primer pair 2 has partial homology with the genomic region used
in the cobas 4800 CT/NG Test (i.e., DR-9 region) and primer pairs 8-3 and 13 have partial homology
with the genomic targets used in the BD ProbeTec Amplified DNA Assays (i.e., chromosomal pilin
gene-inverting protein homologue). In our assay, primer pair 2 did not amplify one N. gonorrhoeae
isolate. Furthermore, cross-reactivity of primer pairs 8-3 and 13 with 3 and 7 other non-gonococcal
Neisseria species respectively was observed. Cross-reactivity with Neisseria subflava and Neisseria
lactamica was also reported for the BD ProbeTec GC Qx Amplified DNA Assay [8].
4. Materials and Methods
4.1. Bacterial Strains
To determine the sensitivity and specificity of primer pairs developed by us for the identification
of N. gonorrhoeae, DNA from 145 N. gonorrhoeae isolates was obtained from the Dillon Culture Collection
and represented isolates from diverse geographical areas [26–28] (Table 4: Panel 1). These isolates
included the World Health Organization (WHO) N. gonorrhoeae reference isolates M, L, F, B, O, C, P,
K, G, and N [29]. A random collection of 40 other Neisseria and non-Neisseria species were obtained
from the National Microbiology Laboratory (NML), Winnipeg MB, Canada (Table 4: Panel 1).
For experiments evaluating the hydrogel platform, DNA from 50 cultured N. gonorrhoeae isolates
was used (Table 4: Panel 2 is a sub-panel of Panel 1). WHO N. gonorrhoeae reference strains WHO-F, P,
G, K and N were used as positive controls. Five non-N. gonorrhoeae and non-Neisseria species (E. coli,
L. jensenii, N. elongata, N. subflava, and S. enterica serovar Typhimurium) were used as negative controls.
4.2. DNA Extraction
DNA extraction was performed with a QIAamp DNA Mini Kit (#51306 Qiagen Canada) according
to manufacture’s instructions. DNA was quantified using a NanoDrop 1000 Spectrophotometer
(Thermo Fisher Scientific Inc., Wilmington DE, USA) and the final concentration was adjusted to 50, 70,
or 100 ng/µL for evaluating the hydrogel method.
4.3. Design of Diagnostic Primer Pairs
Non-homologous sequence regions between N. gonorrhoeae FA1090 and N. meningitidis (MC58,
FAM18 and Z2491) were extracted from the N. gonorrhoeae FA1090 genome. These sequences were
then BLASTed against 25 in-house sequenced N. gonorrhoeae genomes and 15 N. gonorrhoeae genomes
available at the Broad Institute database. Sequences which were positive in this BLAST search
(50 sequences) were then further aligned against the NCBI non-redundant (nr) database using
the BLAST program. Regions which were only found in N. gonorrhoeae were filtered for further
analysis. Targets for all primer pairs are present in multiple copies in the N. gonorrhoeae FA1090
genome and in turn increase the sensitivity of detection even at lower DNA concentrations. Based
on these findings, eleven primer pairs were designed using Primer-BLAST [36] (Table 1). Potential
cross-reactivity of the primer pairs was evaluated in silico using primer-BLAST software against
the NCBI nr database. Primer pairs were tested in vitro for their sensitivity and specificity with
N. gonorrhoeae, non-N. gonorrhoeae and non-Neisseria species.
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4.4. Limit of Detection of Primers
RT-PCR reactions contained 5 µL of 2× SYBR-Green master mix (Cat # 4472912, Life Technologies
Inc.), 0.25 µL of each primer (10 µM), 1 µL of DNA (50 ng/µL), and 3.5 µL PCR-grade water in a total
10 µL reaction volume. Initial holding and activation of DNA polymerase was at 50 ◦C for 2 minutes.
RT-PCR was performed for 40 cycles of 95 ◦C for 20 seconds and 60 ◦C for 40 seconds. A post-PCR melt
curve was performed between 60 ◦C to 95 ◦C with 0.3 ◦C temperature increments. Limit-of-detection
assays, using serial dilutions (100 ng/µL to 0.00001 ng/µL) of DNA from N. gonorrhoeae reference
strains WHO F, P, G, K, and N, were used to ascertain the sensitivity of each primer pair. DNA from
40 non-N. gonorrhoeae and non-Neisseria species was also used to test the specificity of each primer pair.
4.5. Real Time PCR and Hydrogel Methods
To compare hydrogel and RT-PCR methods, DNA was amplified using three N. gonorrhoeae
diagnostic primer pairs (3, 17-1, and 21-5) and a SYBR Select master mix. For the RT-PCR control
method, each reaction contained 2 µL DNA (50, 70, or 100 ng/µL), 1.5 µL of each primer (10 µM)
and 5 µL 2× SYBR-Green master mix in a total 10 µL reaction volume. For the hydrogel method,
each reaction contained 1 µL DNA (50, 70, or 100 ng/µL), 0.38 µL of each primer (10 µM), and 8.24 µL
PCR-grade water. 2× SYBR-Green and primers were pre-mixed with the hydrogel. DNA and water
were added to the hydrogel immediately before the start of the RT-PCR assay. Initial holding and
activation of DNA polymerase was at 50 ◦C for 2 minutes. RT-PCR was then performed for 30 cycles of
95 ◦C for 20 seconds and 60 ◦C for 40 seconds. A post PCR melt curve was performed between 60 ◦C
to 95 ◦C with 0.3 ◦C temperature increments.
Various RT-PCR conditions were tested to optimize the hydrogel method. The final
assay conditions included: 30 PCR cycles, 60 ◦C annealing temperature, 60–95 ◦C melt curve
temperature range, 0.3 ◦C image taking temperature increments, and 2× SYBR-Green concentration.
5. Conclusions
The hydrogel method coupled with the primers discussed in this work can meet the ideal rapid
test (ASSURED) criteria established by WHO for STI diagnosis tests; Affordable, Sensitive, Specific,
User-friendly, Robust and Rapid, Equipment-free, and Deliverable to end users [21]. Although the
hydrogel system was evaluated using pure cultures of N. gonorrhoeae, with further optimization the
hydrogel diagnostic method with these primers can be used as a POCT for the diagnosis of gonococci
from clinical specimens enabling rapid, reliable, and efficient diagnosis of N. gonorrhoeae. Furthermore,
multiplex primer pairs can be integrated into the hydrogel platform enabling simultaneous diagnosis
of N. gonorrhoeae and characterization of its AMR profile to different antimicrobials.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/7/3/0070/s1,
Table S1: Primer sequences used in this study for detection of N. gonorrhoeae, their respective targets and copy
numbers present in the N. gonorrhoeae genome.
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